SCHEMBL5830973

SCHEMBL5830973

O=C(Cc1nnc(NS(=O)(=O)c2c(Cl)cc(Cl)cc2Cl)s1)N1CCSCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.53
CCNC P24863 1/20 0.48
CDK8 P49336 1/20 0.48
KMT2A Q03164 7/20 0.40
MEN1 O00255 5/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
KLKB1 P03952 1/20 0.39
CTSB P07858 1/20 0.39
ELANE P08246 1/20 0.39
POLB P06746 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 1/20 0.35
AKT1 P31749 1/20 0.34
IRS1 P35568 1/20 0.34
GAB1 Q13480 1/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B1 P14061 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831162 0.93 HSD11B1 (0.47) HSD11B1CCNCCDK8KMT2AMEN1
SCHEMBL5830900 0.91 HSD11B1 (0.54) HSD11B1CCNCCDK8KMT2AMEN1
SCHEMBL5830495 0.89 HSD11B1 (0.68) HSD11B1CCNCCDK8KMT2AMEN1
SCHEMBL5831036 0.84 CCNC (0.52) HSD11B1CCNCCDK8KMT2AMEN1
SCHEMBL5831200 0.82 HSD11B1 (0.60) HSD11B1CCNCCDK8KMT2AMEN1
SCHEMBL5831094 0.81 HSD11B1 (0.56) HSD11B1KMT2AMEN1ALDH1A1HSD17B1
SCHEMBL3605392 0.80 HSD11B1 (0.80) HSD11B1KMT2AMEN1HTTPOLB
SCHEMBL5830630 0.79 HSD11B1 (0.60) HSD11B1CCNCCDK8KMT2AMEN1
SCHEMBL5831224 0.79 HSD11B1 (0.55) HSD11B1CCNCCDK8KMT2AMEN1
SCHEMBL6610889 0.78 HSD11B1 (0.52) HSD11B1ALDH1A1MAPK1HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885CCNC 4067/4885CDK8 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.